Conversion to Brivaracetam Monotherapy in Clinical Practice: A Retrospective Study.
Antiseizure medication
Brivaracetam
Epilepsy
Focal seizures
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
27
11
2023
accepted:
09
01
2024
pubmed:
1
2
2024
medline:
1
2
2024
entrez:
1
2
2024
Statut:
ppublish
Résumé
The study aimed to evaluate the effectiveness and safety of brivaracetam (BRV) as conversion monotherapy in adults with focal epilepsy treated in the context of real-world clinical practice. This was a retrospective, observational, non-interventional study in adults with focal epilepsy who converted to BRV monotherapy following the withdrawal of background antiseizure medications (ASMs). Primary effectiveness outcome was the retention rate of BRV as single ASM at 6 and 12 months. Secondary outcomes included the 6- and 12-month rates of seizure freedom. Safety and tolerability outcomes included the frequency and type of adverse events (AEs) and the occurrence of treatment discontinuation due to AEs. A total of 44 participants with a median age of 63.5 (interquartile range 44-73.5) years were included; 17 subjects were seizure free at baseline, and 9 of them switched from levetiracetam because of lack of tolerability. The retention rate of BRV monotherapy was 88.6% (39/44) at 6 months and 83.9% (26/31) at 12 months. The rates of seizure freedom were 72.7% (32/44) in subjects with 6-month follow-up and 58.1% (18/31) in subjects with 12-month follow-up. The median maintenance dosage of BRV monotherapy was 150 (100-200) mg/day at 6 months and 125 (100-200) mg/day in subjects with 12-month follow-up. Adverse events were recorded in 6/44 (13.6%) participants and led to BRV discontinuation in 2/44 (4.5%) cases. The reported AEs were somnolence (n = 3), fatigue (n = 2), and irritability (n = 1); no serious AEs were experienced. In 21/44 (47.7%) participants, BRV monotherapy resulted from the direct switch from levetiracetam. The rates of treatment retention and seizure freedom at 6 and 12 months were higher among people who switched from levetiracetam to BRV monotherapy. Brivaracetam may be a valuable treatment of focal seizures in people who converted to monotherapy in a real-life setting.
Identifiants
pubmed: 38300459
doi: 10.1007/s40120-024-00580-2
pii: 10.1007/s40120-024-00580-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
389-398Informations de copyright
© 2024. The Author(s).
Références
Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22.
pubmed: 29403319
pmcid: 5783144
Brivaracetam. Highlight of prescribing information. https://www.briviact.com/briviact-PI.pdf . Accessed Oct 2023.
Moseley BD, Chanteux H, Nicolas JM, Laloyaux C, Gidal B, Stockis A. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163: 106327.
doi: 10.1016/j.eplepsyres.2020.106327
pubmed: 32361205
EMA. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf . Accessed Oct 2023.
Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–4.
doi: 10.1016/j.seizure.2015.03.003
pubmed: 25891931
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–30.
doi: 10.1111/epi.13670
pubmed: 28276060
Lattanzi S, Ascoli M, Canafoglia L, et al. Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures. Epilepsia. 2022;63:e42–50.
doi: 10.1111/epi.17223
pubmed: 35278335
pmcid: 9311068
Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy. Epilepsia. 2023;64:2922–33.
doi: 10.1111/epi.17740
pubmed: 38079181
von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.
doi: 10.7326/0003-4819-147-8-200710160-00010
Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98–103.
doi: 10.1016/j.seizure.2018.07.017
pubmed: 30118932
Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–8.
doi: 10.1016/j.yebeh.2015.09.005
pubmed: 26432008
Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021;118: 107939.
doi: 10.1016/j.yebeh.2021.107939
pubmed: 33839453
Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86:1344–52.
doi: 10.1212/WNL.0000000000002545
pubmed: 26944275
Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82:199–218.
doi: 10.1007/s40265-021-01661-4
pubmed: 35061214
pmcid: 8843918
Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35:1289–301.
doi: 10.1007/s40263-021-00856-3
pubmed: 34476770
pmcid: 8642333
Lattanzi S, Canafoglia L, Canevini MP, et al. Brivaracetam as early add-on treatment in patients with focal seizures: a retrospective, multicenter. Real-World Study Neurol Ther. 2022;11:1789–804.
doi: 10.1007/s40120-022-00402-3
pubmed: 36109431
pmcid: 9588144
Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE—a multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139:360–8.
doi: 10.1111/ane.13059
pubmed: 30506559
Arnold S, Badalamenti V, Diaz A, et al. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase III studies. Epilepsy Res. 2018;141:73–82.
doi: 10.1016/j.eplepsyres.2018.02.005
pubmed: 29486396
Villanueva V, Laloyaux C, D’Souza W, et al. Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records. CNS Drugs. 2023;37:819–35.
doi: 10.1007/s40263-023-01033-4
pubmed: 37684497
pmcid: 10501958
Zahnert F, Krause K, Immisch I, et al. Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol. 2018;9:38.
doi: 10.3389/fneur.2018.00038
pubmed: 29467714
pmcid: 5808159